Diadem Names Clinical Diagnostics Industry Veteran Paul Kinnon as CEO
-—Kinnon Joins to Lead Development and Commercialization of First Minimally Invasive Blood-Based Prognostic Test for Early Alzheimer’s Disease—
—Accessible Early Diagnosis Will Transform Treatment by Enabling Development of Effective Therapeutic Interventions to Slow or Stop Disease Progression—
“Alzheimer’s disease and other dementias are among the greatest public health crises of our time, afflicting more than 50 million people worldwide,” noted Mr. Kinnon. “Development of effective therapies has been hindered by the difficulty of prediction and diagnosis, which makes early, effective intervention impossible.”
Kinnon continued, “Diadem’s transformational technology for the first time makes it possible to diagnose Alzheimer’s early in the disease process and to predict whether the disease will progress. This will allow patients to seek treatment at a time when it is still possible to impact disease progression and preserve function. Our AlzoSure® test is blood-based, non-invasive and potentially widely accessible. I am honored to have the opportunity to work with the talented Diadem team to advance the development and commercialization of this breakthrough technology that could improve the lives of millions.”
Kinnon served as chief executive officer at PredictImmune, publicly traded Transgenomic, and ZyGEM Corp. He held senior executive positions at Life Technologies (now ThermoFisher), Guava Technologies and Cellomics, raising substantial funding, creating global partnerships and increasing shareholder returns. Kinnon has a proven strategic and commercialisation track record of developing and bringing novel technologies and products to global markets rapidly and efficiently. He serves on the boards of both public and private companies and has significant expertise in corporate governance, corporate restructuring, and M&A and divestitures.
“We are delighted to have an experienced and successful global industry veteran like Paul at the helm of our exciting company as it prepares to move into the commercial phase of growth,” said Gerald Möller, Chairman of the Board of Diadem and former CEO of Boehringer Mannheim. “Diadem’s minimally invasive technology for the early diagnosis of Alzheimer’s disease has enormous potential to transform the treatment of dementia and help spur the availability of effective new therapies. We look forward to working with Paul to advance the clinical development and commercialization of this important technology.”
Diadem is developing AlzoSure®—a plasma-based biomarker test that has been validated in early studies to accurately predict the probability a patient with mild cognitive impairment will progress to Alzheimer’s disease. The company’s patented technology measures conformational changes in the p-53 pathway. It targets Unfolded p-53, which is over-expressed in Alzheimer’s patients, using an analytical method that includes a proprietary antibody and target sequences developed by Diadem. Further clinical studies are underway, and the company plans a global launch in collaboration with strategic partners in 2021.